• Policy
• Will Enhertu·Ilaris·morning sickness drugs be reimbursed
• by Lee, Tak-Sun Feb 14, 2024 05:40am

• Policy
• HIRA to revise guidelines on new drugs utility assessment
• by Lee, Tak-Sun Feb 13, 2024 05:52am

• Policy
• Ulcerative colitis drug Omvoh is approved in Korea
• by Lee, Hye-Kyung Feb 13, 2024 05:51am

• Policy
• Janssen’s Spravato required to submit domestic trial data
• by Lee, Hye-Kyung Feb 13, 2024 05:51am

• Policy
• Good pharma companies will receive better drug price
• by Lee, Jeong-Hwan Feb 8, 2024 05:49am

• Policy
• Korean gov. to introduce preferential drug pricing criteria
• by Lee, Jeong-Hwan Feb 8, 2024 05:49am

• Policy
• Production and supply of Cifex Eye Drops is discontinued
• by Lee, Hye-Kyung Feb 8, 2024 05:49am

• Policy
• Preferential pricing possible for non-innovative new drugs
• by Lee, Tak-Sun Feb 8, 2024 05:48am

• Policy
• HIRA 'Ease entry of new drugs and strengthen post-evals'
• by Lee, Tak-Sun Feb 7, 2024 05:59am

• Policy
• Bill for consigned manufacture of advanced biologics
• by Lee, Jeong-Hwan Feb 6, 2024 06:10am